Biopharmaceutical Third-Party Logistics Global Market Report 2024

The biopharmaceutical third-party logistics market size has grown strongly in recent years. It will grow from $131.23 billion in 2023 to $140.68 billion in 2024 at a compound annual growth rate (CAGR) of 7.2%. The growth observed in the historical period can be attributed to the globalization of pharmaceutical supply chains, stringent regulatory requirements, an increase in biopharmaceuticals, and a focus on cold chain logistics.

The biopharmaceutical third-party logistics market size is expected to see strong growth in the next few years. It will grow to $184.35 billion in 2028 at a compound annual growth rate (CAGR) of 7.0%. The anticipated growth in the forecast period can be ascribed to the expansion of personalized medicine, the growth of biologics and biosimilars, the digitalization of the supply chain, the increasing complexity of regulatory compliance, and the impact of COVID-19. Major trends expected in the forecast period include the emergence of on-demand logistics solutions, a focus on sustainability in logistics, advancements in last-mile delivery solutions, the implementation of pharma serialization and traceability, and the development of autonomous logistics.

The anticipated rise in the outsourcing of logistics is expected to fuel the growth of the biopharmaceutical third-party logistics market. The practice of outsourcing logistics involves enlisting the services of a third party to manage some or all of a company's logistical activities. In the realm of biopharmaceutical third-party logistics, this trend is observed in the outsourcing of cryogenic supply chain management to logistics partners. As reported in a December 2021 survey by Gartner Inc., a US-based provider of technological research and consulting, approximately 66% of logistics leaders among 298 supply chain professionals in the US augmented their budget for logistics outsourcing in 2021. Furthermore, an estimated 74% anticipate a further increase within the next two years. Hence, the upward trajectory of outsourcing logistics is anticipated to drive the growth of the biopharmaceutical third-party logistics market.

The introduction of innovative biopharmaceutical products is expected to be a driving force behind the growth of the biopharmaceutical third-party logistics market. Innovative biopharmaceutical products encompass advanced therapeutic substances derived from biological sources, such as monoclonal antibodies or gene therapies. The biopharmaceutical third-party logistics market plays a pivotal role in facilitating the efficient launch of these products by offering streamlined supply chain solutions, ensuring timely and secure distribution, and supporting the intricate logistics associated with bringing these innovative therapies to market. As indicated by The IQVIA Institute for Human Data Science in February 2022, a total of 84 novel active substances were launched in 2021, representing a significant increase from the number launched five years prior. This surge in innovation underscores the resilience of the global biomedical system, showcasing sustained momentum in the speed of pharmaceutical research and development. Therefore, the introduction of innovative biopharmaceutical products is anticipated to drive the growth of the biopharmaceutical third-party logistics market.


Technological advancements stand out as a prominent trend gaining momentum in the biopharmaceutical third-party logistics market. Major companies within this market are strategically launching innovative products to fortify their market position and gain a competitive edge. For example, in November 2022, Celcius Logistics Solutions Pvt Ltd., an India-based logistics services provider, introduced Hyper-Local temperature-controlled delivery services designed for food and pharmaceutical orders. The company's last-mile solution, catering to smaller quantities, is available in nine cities across the country. The hyperlocal approach ensures optimal material quality during transportation by continuously monitoring temperatures in real-time at each stage of the delivery process.

Top players in the biopharmaceutical third-party logistics market are actively engaged in product launches, including the establishment of healthcare logistics sub-brands and the introduction of new temperature-sensitive solutions. These endeavors aim to provide comprehensive logistics solutions for healthcare and pharmaceutical companies, specifically addressing the transportation needs of temperature-sensitive pharma and biopharma products. A healthcare logistics sub-brand, coupled with a new temperature-sensitive solution, signifies a specialized branch within the healthcare logistics sector offering dedicated solutions for transporting items requiring precise temperature control. For instance, in April 2021, CEVA Logistics, a France-based global logistics and supply chain company, unveiled FORPATIENTS healthcare logistics sub-brand with a new temperature-sensitive solution. This initiative encompasses end-to-end healthcare logistics, compliance assurance, and global visibility, catering to the specific requirements of the biopharmaceutical third-party logistics market. The comprehensive service ensures secure and compliant storage and transportation of temperature-sensitive products, playing a crucial role in maintaining product quality and patient safety within the intricate logistics of the biopharmaceutical supply chain.

In March 2022, STG Logistics Inc., a US-based provider of optimized logistics and transportation services, successfully acquired the intermodal division of XPO Logistics Inc. for $710 million. This strategic move enhances STG Logistics' position in the containerized logistics industry, paving the way for further achievements. XPO Logistics Inc. is a US-based provider of asset-based less-than-truckload (LTL) freight transportation and third-party logistics, including biopharma logistics.

Major companies operating in the biopharmaceutical third-party logistics market report are McKesson Corporation, AmerisourceBergen Corporation, United Parcel Service of America Inc., FedEx Corporation, DHL International GmbH, Kuehne + Nagel International AG, SF Express Co Ltd., DB Schenker, CH Robinson Worldwide Inc., Nippon Express Group, Expeditors International of Washington Inc., Sinotrans Limited, XPO Logistics Inc., Kerry Logistics Network Limited, Bollore Logistics, Catalent Inc., Agility Logistics, Almac Group, VersaCold Logistics Services, Cryoport Inc., Agility Logistics Corp, Fisher Clinical Services, CEVA Logistics Inc., LifeScience Logistics, Cold Chain Technologies LLC, Langham Logistics, Airpharm Logistics, Express Courier International, Bio Pharma Logistics, PCI Pharma Services.

North America was the largest region in the biopharmaceutical third party logistics market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical third-party logistics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biopharmaceutical third-party logistics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The primary categories of supply chains in biopharmaceutical third-party logistics are cold chain and non-cold chain. The cold chain specifically pertains to a supply chain that ensures temperature control throughout the transportation of products sensitive to temperature variations. Various services, including transportation, warehousing and storage, among others, are utilized by pharmaceutical and biopharmaceutical companies, medical device companies, hospitals and clinics, and other relevant entities.

The biopharmaceutical third-party logistics market research report is one of a series of new reports that provides biopharmaceutical third-party logistics market statistics, including biopharmaceutical third-party logistics industry global market size, regional shares, competitors with a biopharmaceutical third-party logistics market share, detailed biopharmaceutical third-party logistics market segments, market trends and opportunities, and any further data you may need to thrive in the biopharmaceutical third-party logistics industry. This biopharmaceutical third-party logistics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biopharmaceutical third-party logistics market consists of revenues earned by entities by providing biopharmaceutical third-party logistics such as domestic transportation management, international transportation management, and value-added warehousing and distribution. The market value includes the value of related goods sold by the service provider or included within the service offering. The market value includes the value of related goods sold by the service provider or included within the service offering. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.